RGEN - Repligen Reports Record Quarter Increases 2020 Guidance
At a time when many businesses have been impacted by the financial consequences of the coronavirus pandemic, Repligen (NASDAQ: RGEN) continues to hum along. The bioprocess engineering leader reported record quarterly revenue and profitability in the Q2 2020, and management raised full-year 2020 financial guidance to boot.
Repligen's success isn't too surprising. After investors learned the company's significant dependence on clinical trial activities wasn't expected to weigh down the business during the global health crisis, it was safe to assume Repligen's products would continue to find traction in the market. As it turns out, the business became more important to customers, especially in Asia.
Here's what investors need to know.